State
Regulations Regarding Sterile Compounding
Michael
Pavlik, Pharm. D. Candidate 2017, Ferris State University
Background
USP <797> is a
chapter of the United States Pharmacopeia that outlines proper sterile
compounding and regulations for any pharmacy that produces sterile compounding
products. Before USP <797>, the U.S Food and Drug Administration (FDA)
found that nearly one out of every three sterile compounded products contained
some degree of deficiency. The chapter USP <797> was first published in
2004 to regulate sterile compounding pharmacies and laboratories to guide safer
practices nationally. Since the initial publication, there have been many
revisions to this chapter with the most recent in January of 2016.
As of
April 2012
At the time this article was
published, 8 years have passed since USP chapter <797> became the
national standard for sterile compounding. Despite a national standard, state
laws and regulations vary widely in regard to referencing USP <797>,
whether it be full compliance requirements or no mention at all. In 2011, five states
(including Michigan) had no laws or regulations that reference sterile
compounding or parenteral nutrition practices in any way. The majority of the
remaining states at this time had laws that did not specifically site USP
<797>, but had regulations in place regarding sterile compounding and
parenteral nutrition. Whether or not states had laws and regulations that were
in compliance with, or referenced USP <797>, the average actual
compliance rate was only 73.3 percent With such a large margin of
non-compliance regarding USP <797>, it is not difficult to understand why
new laws and regulations are becoming more popular within states.
Newer
Regulations – June 2014
Governor Rick Snyder signed a
new law that regulates compounding pharmacists and pharmacies for both sterile
and non-sterile pharmaceutical products. This law also included penalties and
sanctions for certain violations. A larger influence for this comprehensive law
was the fungal meningitis outbreak in fall of 2012 in which Michigan suffered
the most infections and highest number of fatalities. This outbreak was tracked
by the Centers for Disease Control and Prevention (CDC) and was attributed to
contaminated epidural steroid injections from a compounding facility in
Massachusetts.
The new comprehensive law amends parts 161 and 177 of the
public health code and includes, but is not limited to, the following:
- Any applicant for a pharmacy license that involves compounding must submit verification of accreditation through a national organization.
- Pharmacies cannot compound commercially available products unless the product is significantly different from an already available product.
- . Any pharmacy charged with a violation out of state or with federal law must notify the Department of Licensing and Regulatory Affairs (LARA) within 30 days.
- There are criminal penalties imposed for violations of certain provisions and requirements and a license may be suspended if an imminent risk to public health or safety is reported from the FDA or CDC.
Current
Regulations in Michigan compared to other states
Since legislature regarding sterile compounding has become
more popular since the meningitis outbreak in 2012, the National Conference of
State Legislators (NCSL) began holding records of state laws on this topic. The
NCSL holds records on whether or not the state compounds sterile preparations,
if they comply with the USP, how many pharmacies are accredited in that state
to compound sterile products (voluntary) and recent additions to sterile
compounding laws within each state. According to the NCSL’s website, 21 states
currently do not practice sterile compounding (16 of which have compounding
pharmacies that are accredited by the Pharmacy Compounding Accreditation Board)
or are pending approval, three states use state regulations instead of USP
regulations and 26 states have pharmacies that compound sterile products and
follow USP regulations. According to the NCSL’s current website, Michigan is
one of the states that does not yet follow USP regulations but has
pharmacies that are accredited by the Pharmacy Compounding Accreditation Board.
Michigan’s
newest laws regarding sterile compounding were released in 2014 and signed by
Governor Snyder including those outlined above. These new laws distinguish
Michigan from other states in a number of ways. In Florida, for example, a
sterile compounding facility must apply for a permit from the state instead of
a national accreditation program. The sterile compounding permit requires a
background and history check, and has statues that outline punishment for
failure to comply. In Texas, it is also illegal to compound sterile products
that are commercially available and the pharmacy must also receive national
accreditation status. Since the early 2010s, regulations requiring national or
state accreditation have become ubiquitous to ensure safer compounding measures
for sterile compounds. More stringent guidelines for accreditation and sterile
compounding practice have been implemented, and pharmacies across the nation
have been increasingly compliant with new standards. As time goes on, there
will likely be a continuous reevaluation and adaptation to sterile compounding
standards across the nation.
References
http://www.pharmacy.texas.gov/files_pdf/comparison%20final.pdf
http://www.michigan.gov/documents/lara/Compounding_Pharmacy_New_Law_Memo_09-2014_468552_7.pdf
http://floridaspharmacy.gov/licensing/sterile-compounding-permit/
http://www.pppmag.com/article/1113/april_2012_state_of_pharmacy_compounding/state_regulations_impact_usp_797_compliance/